This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Thermo Fisher Scientific (TMO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Thermo Fisher (TMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Thermo Fisher Scientific (TMO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (TMO) Outperforming Other Medical Stocks This Year?
Thermo Fisher Gets a Boost from Buyouts and Global Expansion
by Urmimala Biswas
Thermo Fisher (TMO) registers a solid international performance with strong growth in Europe and Asia-Pacific including China.
The Zacks Analyst Blog Highlights: Microsoft, Royal Dutch, IBM, Thermo Fisher and American Tower
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, Royal Dutch, IBM, Thermo Fisher and American Tower
Top Stock Reports for Microsoft, Royal Dutch Shell & IBM
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Royal Dutch Shell (RDS.A) and IBM (IBM).
Thermo Fisher Closes API Site Buyout, Fortifies Pharma Unit
by Zacks Equity Research
Following the acquisition closure of GlaxoSmithKline's plant, Thermo Fisher (TMO) will continue to manufacture APIs for the same under a multi-year supply agreement.
Here's Why You Should Add Thermo Fisher to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher's (TMO) performance.
Zacks.com featured highlights include: Booz Allen Hamilton, Thermo Fisher Scientific, Target, Microsoft and Barrel Old Country Store
by Zacks Equity Research
Zacks.com featured highlights include: Booz Allen Hamilton, Thermo Fisher Scientific, Target, Microsoft and Barrel Old Country Store
7 Dividend Growth Stocks to Buy for October
by Sweta Killa
Dividend-paying securities are a major source of consistent income for investors when returns from the equity market are at risk.
Roper (ROP) Agrees to Sell Gatan to AMETEK for $925M in Cash
by Zacks Equity Research
Roper's (ROP) Gatan divestment, to be completed in the fourth quarter of 2019, will help it concentrate on its core and profitable businesses.
Is Thermo Fisher Scientific (TMO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (TMO) Outperforming Other Medical Stocks This Year?
4 Stocks to Focus on Global Biotechnology Reagents Market
by Zacks Equity Research
Increased use of reagents in the field of research, bioscience and genetics is pushing the biotechnology reagents market higher.
The Zacks Analyst Blog Highlights: AT&T, Thermo Fisher, Schwab, Veeva and PVH
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AT&T, Thermo Fisher, Schwab, Veeva and PVH
Here's Why You Should Hold on to Thermo Fisher (TMO) for Now
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher's (TMO) performance.
Top Stock Reports for AT&T, Thermo Fisher & Schwab
by Mark Vickery
Today's Research Daily features updated research reports on 16 major stocks, including AT&T (T), Thermo Fisher (TMO) and Schwab (SCHW).
Semtech (SMTC) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Semtech's (SMTC) fiscal second-quarter results may be affected by China demand softness and competition. However, differentiated growth drivers and diversification might aid its earnings.
Thermo Fisher (TMO) Down 4.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What's in the Cards for AMETEK (AME) This Earnings Season?
by Zacks Equity Research
AMETEK's (AME) Q2 earnings are likely to be driven by strong organic growth and contributions from acquisitions. Yet, ongoing trade tensions might affect its upcoming results.
What's in the Cards for Expedia Group's (EXPE) Q2 Earnings?
by Zacks Equity Research
Strength across segments is likely to drive Expedia Group's (EXPE) second-quarter revenues.
The Zacks Analyst Blog Highlights: Comcast, Thermo Fisher, McDonald's, Canadian National and NextEra
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Comcast, Thermo Fisher, McDonald's, Canadian National and NextEra
Thermo Fisher (TMO) Beats on Q2 Earnings, Lifts Guidance
by Zacks Equity Research
Banking on a strong operational performance, Thermo Fisher (TMO) raises its 2019 revenue and earnings guidance.
Thermo Fisher Scientific (TMO) Beats Q2 Earnings Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 1.00% and -0.03%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Can Home Health Growth Support Amedisys' (AMED) Q2 Earnings?
by Zacks Equity Research
Within Home Health, Amedisys (AMED) is expected to boost same-store volumes in Q2 via higher admissions and re-certifications.
Can New Product Menu Aid Zimmer Biomet's (ZBH) Q2 Earnings?
by Zacks Equity Research
With consecutive product approvals, Zimmer Biomet (ZBH) becomes the first company on the global frontier with 510(k) clearance for Brain, Spine and Knee offerings on a single robotic platform.
Why Earnings Season Could Be Great for Thermo Fisher (TMO)
by Zacks Equity Research
Thermo Fisher (TMO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.